Cordon-Cardo C
Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Mod Pathol. 2001 Mar;14(3):254-7. doi: 10.1038/modpathol.3880294.
Solid tumor diagnosis is now entering an era in which molecular genetics plays an important role. Clinical trials have shown different responses to various therapies that correlate with molecular alterations. Biological determinants related to treatment response markers aimed at individualized therapies are being defined and implemented. Patients are now being treated based on the profile of molecular genetic alterations in individual tumors. Protocols based on molecular markers will increase the chances for cure by opting for the right management approach. They also will improve, in most situations, the quality of life of patients with cancer, for example by facilitating organ preservation strategies. The molecular characterization therefore has an important prognostic and practical role in diagnosis.
实体瘤诊断如今正进入一个分子遗传学发挥重要作用的时代。临床试验表明，针对各种疗法的不同反应与分子改变相关。与旨在实现个体化治疗的治疗反应标志物相关的生物学决定因素正在被确定和应用。现在，患者正基于个体肿瘤中的分子遗传学改变情况接受治疗。基于分子标志物的方案通过选择正确的管理方法将增加治愈的机会。在大多数情况下，它们还将改善癌症患者的生活质量，例如通过促进器官保留策略。因此，分子特征在诊断中具有重要的预后和实际作用。
